Uncategorized
IOP increase seen with Ozurdex common but easily managed
LONDON — A subanalysis of data from the MEAD study showed increased IOP resulting from use of Ozurdex for the treatment of diabetic macular edema was well-managed with medication and did not affect visual and anatomic outcomes, a speaker here said.Three-year results of the study, which included 1,048 patients, demonstrated the efficacy of Ozurdex (dexamethasone 0.7 mg intravitreal implant, Allergan); however, increased IOP was common, according to Rubens Belfort Jr., MD, PhD.